Business Context and Reporting Period
Company: Alkermes Plc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 2, 2018
Event: Regulation FD Disclosure regarding FDA approval of a new pharmaceutical product.
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the U.S. Food and Drug Administration (FDA) approval of ARISTADA INITIO (aripiprazole lauroxil). This product is approved to be administered in combination with a single 30 mg dose of oral aripiprazole for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults.
Guidance, Outlook, and Risks
- Outlook: The company anticipates a commercial launch of ARISTADA INITIO in the U.S., though specific timing is not guaranteed.
- Forward-Looking Statements: The filing includes statements regarding the commercialization and potential therapeutic value of the product. Management cautions that these are not promises or guarantees.
- Risks and Uncertainties:
- Uncertainty regarding the commercial availability date.
- Risk that pharmacokinetic and safety results from studies may not predict commercial results.
- Potential failure to commercialize successfully.
- Uncertainty regarding third-party payer coverage or reimbursement.
Investor Verification Checklist
- Verify the specific launch date for ARISTADA INITIO once announced.
- Monitor third-party payer coverage decisions and reimbursement rates for the new initiation regimen.
- Review the "Risk Factors" section in the company's Annual Report on Form 10-K for the year ended December 31, 2017, for detailed risk disclosures.
- Track future press releases for updates on the commercial performance of ARISTADA and ARISTADA INITIO.